Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Expert Review of Anticancer Therapy

• Publication date

  2010-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/era.09.175PMID 20131990
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function.

  2010cited by this paper
• Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT

  2010cited by this paper
• Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly pat

  2009cited by this paper
• A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy.

  2009cited by this paper
• Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.

  2009cited by this paper
• Palonosetron (Aloxi®) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy

  2009cited by this paper
• Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.

  2009cited by this paper
• Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.

  2009cited by this paper
• Is there a preferred dose of palonosetron? Results of an abstracted data (AD) meta-analysis (MA) of all eight randomized double-blind (RDB) studies and the impact on guideline considerations.

  2009cited by this paper
• Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy

  2009cited by this paper
• Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results

  2009cited by this paper
• A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy.

  2009cited by this paper
• Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy

  2008cited by this paper
• Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children.

  2008cited by this paper
• Randomized, placebo‐controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting

  2008cited by this paper
• The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial

  2008cited by this paper
• Palonosetron Exhibits Unique Molecular Interactions with the 5-HT3 Receptor

  2008cited by this paper
• Physical and chemical stability of palonosetron with metoclopramide and promethazine during simulated y-site administration.

  2007cited by this paper
• A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study

  2007cited by this paper
• Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration.

  2007cited by this paper
• Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer

  2007cited by this paper
• Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated y-site administration.

  2006cited by this paper
• Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.

  2006cited by this paper
• A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.

  2006cited by this paper
• Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment.

  2006cited by this paper
• Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.

  2006cited by this paper
• Palonosetron HCl Compatibility and Stability with Doxorubicin HCl and Epirubicin HCl During Simulated Y-Site Administration

  2005cited by this paper
• Evaluation of Safety and Pharmacokinetics of Consecutive Multiple‐Day Dosing of Palonosetron in Healthy Subjects

  2005cited by this paper
• Compatibility of palonosetron with cyclophosphamide and with ifosfamide during simulated Y-site administration.

  2005cited by this paper
• Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers

  2005cited by this paper
• Physical and chemical stability of palonosetron hydrochloride with Fluorouracil and with gemcitabine hydrochloride during simulated y-site administration.

  2005cited by this paper
• Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated y-site administration.

  2005cited by this paper
• Physical and chemical stability of palonosetron hydrochloride with Lorazepam and midazolam hydrochloride during simulated y-site administration.

  2005cited by this paper
• Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.

  2005cited by this paper
• Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study.

  2004cited by this paper
• Pharmacokinetics, metabolism and excretion of intravenous [l4C]‐palonosetron in healthy human volunteers

  2004cited by this paper
• Physical and Chemical Stability of Palonosetron HCl in 4 Infusion Solutions

  2004cited by this paper
• Compatibility and stability of aloxi (palonosetron hydrochloride) admixed with dexamethasone sodium phosphate.

  2004cited by this paper
• Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin, and oxaliplatin during simulated Y-site administration

  2004cited by this paper
• Pharmacokinetic and Safety Evaluation of Palonosetron, a 5‐Hydroxytryptamine‐3 Receptor Antagonist, in U.S. and Japanese Healthy Subjects

  2004cited by this paper
• Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration.

  2004cited by this paper
• Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy‐induced nausea and vomiting

  2003cited by this paper
• Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonist

  2003cited by this paper
• Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.

  2003cited by this paper
• The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.

  2003cited by this paper
• TWO KINDS OF TRYPTAMINE RECEPTOR

  1997cited by this paper
• On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993.

  1996cited by this paper
• Pharmacological characterization of RS 25259‐197, a novel and selective 5‐HT3 receptor antagonist, in vivo

  1995cited by this paper
• Molecular biology of serotonin receptors.

  1995cited by this paper
• The interaction of RS 25259‐197, a potent and selective antagonist, with 5‐HT3 receptors, in vitro

  1995cited by this paper
• Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis

  1992cited by this paper
• Molecular biology of serotonin receptors.

  1992cited by this paper
• Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian Group For Antiemetic Research.

  1992cited by this paper
• Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.

  1990cited by this paper
• GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.

  1989cited by this paper
• Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist.

  1987cited by this paper
• Inhibition of cisplatin‐induced vomiting by selective 5‐hydroxytryptamine M‐receptor antagonism

  1986cited by this paper
• On the receiving end--patient perception of the side-effects of cancer chemotherapy.

  1983cited by this paper
• Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting.

  1981cited by this paper
• Tryptamine receptors

  1953cited by this paper
• Serum vasoconstrictor (serotonin) the presence of creatinine in the complex; a proposed structure of the vasoconstrictor principle.

  1949cited by this paper
• Partial purification of the vasoconstrictor in beef serum.

  1948cited by this paper

• Palonosetron Hydrochloride

  2020cites this paper
• Comparative Study of Ondansetron Verses Palonosetron in Cisplatin Induced Nausea Vomiting

  2018cites this paper
• Product Data Sheet Inhibitors • A gonists

  2018cites this paper
• Economic evaluation of 5-HT3 receptor antagonists in combination with dexamethasone for the prevention of ‘overall’ nausea and vomiting following highly emetogenic chemotherapy in Chinese adult patients

  2017cites this paper
• Prevention and management of chemotherapy-induced nausea and vomiting.

  2015cites this paper
• Randomized Pharmacokinetic Study Comparing Subcutaneous and Intravenous Palonosetron in Cancer Patients Treated with Platinum Based Chemotherapy

  2014cites this paper
• Anesthetic premedication: new horizons of an old practice.

  2014cites this paper
• Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin—a phase II study

  2013cites this paper
• Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy

  2013cites this paper
• Management of chemotherapy-induced nausea and vomiting: A pilot randomised controlled trial using Nevasic audio programme.

  2013cites this paper
• Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy

  2012cites this paper
• Antiemetic Treatment for Gastroparesis

  2012cites this paper
• Liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry method for the quantitation of palonosetron in human plasma and urine: Application to a pharmacokinetic study.

  2012cites this paper
• Palonosetron versus other 5-HT3 receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States

  2011cites this paper
• Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.

  2011cites this paper